Pauline Ho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pauline Ho has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Anne Barton
Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester , Manchester
6 shared publications - Ryan Malcolm Hum
Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
4 shared publications - Darren Plant
Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester , Manchester
3 shared publications - Maya H. Buch
University of Manchester
3 shared publications - Yvonne Tan
Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
3 shared publications - Paul Martin
Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
2 shared publications
Latest Publications
- Open Access
Redefining Synovial Pathotypes in Psoriatic Arthritis through Multi-Modal Histology and Machine Learning (The PSYNOVIUM Study)
Background: Synovial inflammation in psoriatic arthritis (PsA) lacks a validated histological classification framework. Current approaches apply rheumatoid arthritis (RA) synovial pathotypes to PsA, which overlooks immunobiological differences between the diseases and limits the predictive power of tissue stratification. We aimed to define data-driven, PsA-specific synovial pathotypes to facilitate tissue-driven precision medicine. Methods: In this cross-sectional study, ultrasound-guided synovial biopsies were obtained from 61 patients with PsA (n=22), seropositive RA (n=23), seronegative RA (n=10), and other inflammatory arthritides (n=6). Sections underwent multi-modal staining, including H&E, picrosirius red, and immunohisto-chemistry for CD3, CD20, CD68, CD138, and CD31. Whole-slide digital image analysis and automated pixel classifiers quantified cellular and stromal metrics. Unsupervised hierarchical clustering identified intrinsic PsA pathotypes, which were correlated with clinical disease activity, radiographic osteoarthritis (OA), and longitudinal treatment responses. Findings: While a subset of PsA patients shared an inflammatory signature with seropositive RA, unsupervised clustering of the PsA cohort revealed three distinct, novel pathotypes: ‘Dense Myeloid’ (macrophage-driven), ‘Fibro-Stromal’ (fibrosis and pauci-immune), and ‘Angio-Lymphoid’ (hypervascular with significant CD138 + plasma cell infiltration). Pathotypes were independent of treatment and concurrent radiographic knee OA. The Fibro-Stromal pathotype correlated with significantly higher cutaneous psoriasis severity. Longitudinally, patients with the Fibro-Stromal pathotype exhibited a trend toward lower treatment response (44%) following standard interventions (methotrexate or TNF inhibitors) compared to the Dense Myeloid (50%) and Angio-Lymphoid (80%) pathotypes. Interpretation: We present the first computationally derived synovial pathotypes specific to PsA, revealing distinct plasma cell and fibrotic architectures not captured by RA-centric models. To enable clinical translation, we distilled these findings into a pragmatic, four-marker diagnostic decision tree (CD31, CD68, CD138, and picrosirius red) designed for routine histopathology workflows, providing a staging ground for biomarker-stratified clinical trials in PsA. Funding: Funding from the NIHR Biomedical Research Centre: Manchester, Arthritis UK, the Wellcome Trust, Brit-PACT, the National Psoriasis Foundation, and the Medical Research Council. Research in context: Evidence before this study: The potential clinical utility of tissue-based patient stratification is well established in rheumatoid arthritis (RA), where baseline synovial pathotypes (lympho-myeloid, diffuse-myeloid, and pauciimmune) have guided targeted biologic therapy in landmark precision medicine trials. However, psoriatic arthritis (PsA) exhibits a fundamentally distinct synovial microenvironment, characterised by unique vascular architecture, altered stromal fibroblast phenotypes, and distinct immune infiltrates intertwined with the IL-23/IL-17 cytokine axis. Consequently, attempting to classify PsA synovial tissue using established RA-derived scoring systems risks misrepresenting intrinsic disease biology. There is currently no validated, disease-specific histological classification system for PsA, which forces therapeutic decision-making to rely on an empirical, trial-and-error approach rather than underlying target tissue pathobiology. Added value of this study: To our knowledge, this is the first study to define data-driven, computationally derived synovial pathotypes entirely specific to PsA. By leveraging multi-modal digital pathology and unsupervised machine learning, we deconstructed the PsA synovium into three biologically distinct pathotypes: Dense Myeloid, Fibro-Stromal, and Angio-Lymphoid. We demonstrated that the highly inflammatory PsA microenvironment is distinctly driven by CD138 + plasma cells rather than the CD20 + B cells typically observed in RA. Furthermore, we identified a striking tissue-level divergence: patients with the highly fibrotic, pauci-immune Fibro-Stromal pathotype exhibited the most severe cutaneous psoriasis and demonstrated a trend toward higher failure rates on standard therapies, independent of concurrent osteoarthritis. Crucially, we translated these high-dimensional computational findings into a pragmatic, four-marker diagnostic decision tree (incorporating CD31, CD68, CD138, and picrosirius red). Implications of all the available evidence: This study establishes that PsA synovial pathology requires a dedicated, disease-specific classification framework. The proposed diagnostic decision tree can be integrated into routine clinical histopathology workflows without the immediate need for advanced spatial or single-cell transcriptomics. Furthermore, the correlation between the Fibro-Stromal pathotype, severe skin disease, and poor joint response to standard therapies provides a biological rationale for stratifying this specific subgroup towards early IL-17 or IL-23 inhibitor intervention alongside conventional synthetic disease-modifying antirheumatic drugs. Ultimately, these novel PsA pathotypes provide the vital staging ground required to design and execute biomarker-stratified, tissue-driven clinical trials, paving the way for precision medicine in PsA.
Open AccessRedefining Synovial Pathotypes in Psoriatic Arthritis through Multi-Modal Histology and Machine Learning (The PSYNOVIUM Study)
Background: Synovial inflammation in psoriatic arthritis (PsA) lacks a validated histological classification framework. Current approaches apply rheumatoid arthritis (RA) synovial pathotypes to PsA, which overlooks immunobiological differences between the diseases and limits the predictive power of tissue stratification. We aimed to define data-driven, PsA-specific synovial pathotypes to facilitate tissue-driven precision medicine. Methods: In this cross-sectional study, ultrasound-guided synovial biopsies were obtained from 61 patients with PsA (n=22), seropositive RA (n=23), seronegative RA (n=10), and other inflammatory arthritides (n=6). Sections underwent multi-modal staining, including H&E, picrosirius red, and immunohisto-chemistry for CD3, CD20, CD68, CD138, and CD31. Whole-slide digital image analysis and automated pixel classifiers quantified cellular and stromal metrics. Unsupervised hierarchical clustering identified intrinsic PsA pathotypes, which were correlated with clinical disease activity, radiographic osteoarthritis (OA), and longitudinal treatment responses. Findings: While a subset of PsA patients shared an inflammatory signature with seropositive RA, unsupervised clustering of the PsA cohort revealed three distinct, novel pathotypes: ‘Dense Myeloid’ (macrophage-driven), ‘Fibro-Stromal’ (fibrosis and pauci-immune), and ‘Angio-Lymphoid’ (hypervascular with significant CD138 + plasma cell infiltration). Pathotypes were independent of treatment and concurrent radiographic knee OA. The Fibro-Stromal pathotype correlated with significantly higher cutaneous psoriasis severity. Longitudinally, patients with the Fibro-Stromal pathotype exhibited a trend toward lower treatment response (44%) following standard interventions (methotrexate or TNF inhibitors) compared to the Dense Myeloid (50%) and Angio-Lymphoid (80%) pathotypes. Interpretation: We present the first computationally derived synovial pathotypes specific to PsA, revealing distinct plasma cell and fibrotic architectures not captured by RA-centric models. To enable clinical translation, we distilled these findings into a pragmatic, four-marker diagnostic decision tree (CD31, CD68, CD138, and picrosirius red) designed for routine histopathology workflows, providing a staging ground for biomarker-stratified clinical trials in PsA. Funding: Funding from the NIHR Biomedical Research Centre: Manchester, Arthritis UK, the Wellcome Trust, Brit-PACT, the National Psoriasis Foundation, and the Medical Research Council. Research in context: Evidence before this study: The potential clinical utility of tissue-based patient stratification is well established in rheumatoid arthritis (RA), where baseline synovial pathotypes (lympho-myeloid, diffuse-myeloid, and pauciimmune) have guided targeted biologic therapy in landmark precision medicine trials. However, psoriatic arthritis (PsA) exhibits a fundamentally distinct synovial microenvironment, characterised by unique vascular architecture, altered stromal fibroblast phenotypes, and distinct immune infiltrates intertwined with the IL-23/IL-17 cytokine axis. Consequently, attempting to classify PsA synovial tissue using established RA-derived scoring systems risks misrepresenting intrinsic disease biology. There is currently no validated, disease-specific histological classification system for PsA, which forces therapeutic decision-making to rely on an empirical, trial-and-error approach rather than underlying target tissue pathobiology. Added value of this study: To our knowledge, this is the first study to define data-driven, computationally derived synovial pathotypes entirely specific to PsA. By leveraging multi-modal digital pathology and unsupervised machine learning, we deconstructed the PsA synovium into three biologically distinct pathotypes: Dense Myeloid, Fibro-Stromal, and Angio-Lymphoid. We demonstrated that the highly inflammatory PsA microenvironment is distinctly driven by CD138 + plasma cells rather than the CD20 + B cells typically observed in RA. Furthermore, we identified a striking tissue-level divergence: patients with the highly fibrotic, pauci-immune Fibro-Stromal pathotype exhibited the most severe cutaneous psoriasis and demonstrated a trend toward higher failure rates on standard therapies, independent of concurrent osteoarthritis. Crucially, we translated these high-dimensional computational findings into a pragmatic, four-marker diagnostic decision tree (incorporating CD31, CD68, CD138, and picrosirius red). Implications of all the available evidence: This study establishes that PsA synovial pathology requires a dedicated, disease-specific classification framework. The proposed diagnostic decision tree can be integrated into routine clinical histopathology workflows without the immediate need for advanced spatial or single-cell transcriptomics. Furthermore, the correlation between the Fibro-Stromal pathotype, severe skin disease, and poor joint response to standard therapies provides a biological rationale for stratifying this specific subgroup towards early IL-17 or IL-23 inhibitor intervention alongside conventional synthetic disease-modifying antirheumatic drugs. Ultimately, these novel PsA pathotypes provide the vital staging ground required to design and execute biomarker-stratified, tissue-driven clinical trials, paving the way for precision medicine in PsA.
- Open Access
- 7 November 2026
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 2 (4)
Synovial and serum S100A4 expression in rheumatoid arthritis is observed across disease stages and synovial pathotypes
- 7 November 2026
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 2 (4)
Open AccessSynovial and serum S100A4 expression in rheumatoid arthritis is observed across disease stages and synovial pathotypes
- Open Access
- 25 December 2025
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 2 (1) , 36-41
Characterising subgroups of difficult-to-treat rheumatoid arthritis in real-world clinical settings
- 25 December 2025
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 2 (1) , 36-41
Open AccessCharacterising subgroups of difficult-to-treat rheumatoid arthritis in real-world clinical settings
- Open Access
- 17 January 2024
- Published by Wiley in Arthritis & Rheumatology
- Vol. 76 (5) , 696-703
Using Polygenic Risk Scores to Aid Diagnosis of Patients With Early Inflammatory Arthritis: Results From the Norfolk Arthritis Register
Objective: There is growing evidence that genetic data are of benefit in the rheumatology outpatient setting by aiding early diagnosis. A genetic probability tool (G‐PROB) has been developed to aid diagnosis has not yet been tested in a real‐world setting. Our aim was to assess whether G‐PROB could aid diagnosis in the rheumatology outpatient setting using data from the Norfolk Arthritis Register (NOAR), a prospective observational cohort of patients presenting with early inflammatory arthritis.Methods: Genotypes and clinician diagnoses were obtained from patients from NOAR. Six G‐probabilities (0%–100%) were created for each patient based on known disease‐associated odds ratios of published genetic risk variants, each corresponding to one disease of rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, spondyloarthropathy, gout, or “other diseases.” Performance of the G‐probabilities compared with clinician diagnosis was assessed.Results: We tested G‐PROB on 1,047 patients. Calibration of G‐probabilities with clinician diagnosis was high, with regression coefficients of 1.047, where 1.00 is ideal. G‐probabilities discriminated clinician diagnosis with pooled areas under the curve (95% confidence interval) of 0.85 (0.84–0.86). G‐probabilities 2 unlikely diseases for 94% of patients and >3 for 53.7% of patients. G‐probabilities >50% corresponded to a positive predictive value of 70.4%. In 55.7% of patients, the disease with the highest G‐probability corresponded to clinician diagnosis.Conclusion: G‐PROB converts complex genetic information into meaningful and interpretable conditional probabilities, which may be especially helpful at eliminating unlikely diagnoses in the rheumatology outpatient setting. image
- 17 January 2024
- Published by Wiley in Arthritis & Rheumatology
- Vol. 76 (5) , 696-703
Open AccessUsing Polygenic Risk Scores to Aid Diagnosis of Patients With Early Inflammatory Arthritis: Results From the Norfolk Arthritis Register
Objective: There is growing evidence that genetic data are of benefit in the rheumatology outpatient setting by aiding early diagnosis. A genetic probability tool (G‐PROB) has been developed to aid diagnosis has not yet been tested in a real‐world setting. Our aim was to assess whether G‐PROB could aid diagnosis in the rheumatology outpatient setting using data from the Norfolk Arthritis Register (NOAR), a prospective observational cohort of patients presenting with early inflammatory arthritis.Methods: Genotypes and clinician diagnoses were obtained from patients from NOAR. Six G‐probabilities (0%–100%) were created for each patient based on known disease‐associated odds ratios of published genetic risk variants, each corresponding to one disease of rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, spondyloarthropathy, gout, or “other diseases.” Performance of the G‐probabilities compared with clinician diagnosis was assessed.Results: We tested G‐PROB on 1,047 patients. Calibration of G‐probabilities with clinician diagnosis was high, with regression coefficients of 1.047, where 1.00 is ideal. G‐probabilities discriminated clinician diagnosis with pooled areas under the curve (95% confidence interval) of 0.85 (0.84–0.86). G‐probabilities 2 unlikely diseases for 94% of patients and >3 for 53.7% of patients. G‐probabilities >50% corresponded to a positive predictive value of 70.4%. In 55.7% of patients, the disease with the highest G‐probability corresponded to clinician diagnosis.Conclusion: G‐PROB converts complex genetic information into meaningful and interpretable conditional probabilities, which may be especially helpful at eliminating unlikely diagnoses in the rheumatology outpatient setting. image
- Open Access
- 5 September 2022
- Published by Elsevier in Neuromuscular Disorders
- Vol. 32 (10) , 785-789
SARS-CoV-2 vaccination and new-onset myasthenia gravis: A report of 7 cases and review of the literature
- 5 September 2022
- Published by Elsevier in Neuromuscular Disorders
- Vol. 32 (10) , 785-789
Open AccessSARS-CoV-2 vaccination and new-onset myasthenia gravis: A report of 7 cases and review of the literature
- Open Access
- 21 January 2017
- Published by Springer Nature in BMC Microbiology
- Vol. 17 (1) , 1-12
Optimisation of methods for bacterial skin microbiome investigation: primer selection and comparison of the 454 versus MiSeq platform
The composition of the skin microbiome is predicted to play a role in the development of conditions such as atopic eczema and psoriasis. 16S rRNA gene sequencing allows the investigation of bacterial microbiota. A significant challenge in this field is development of cost effective high throughput methodologies for the robust interrogation of the skin microbiota, where biomass is low. Here we describe validation of methodologies for 16S rRNA (ribosomal ribonucleic acid) gene sequencing from the skin microbiome, using the Illumina MiSeq platform, the selection of primer to amplify regions for sequencing and we compare results with the current standard protocols.. DNA was obtained from two low density mock communities of 11 diverse bacterial strains (with and without human DNA supplementation) and from swabs taken from the skin of healthy volunteers. This was amplified using primer pairs covering hypervariable regions of the 16S rRNA gene: primers 63F and 519R (V1-V3); and 347F and 803R (V3-V4). The resultant libraries were indexed for the MiSeq and Roche454 and sequenced. Both data sets were denoised, cleaned of chimeras and analysed using QIIME. There was no significant difference in the diversity indices at the phylum and the genus level observed between the platforms. The capture of diversity using the low density mock community samples demonstrated that the primer pair spanning the V3-V4 hypervariable region had better capture when compared to the primer pair for the V1-V3 region and was robust to spiking with human DNA. The pilot data generated using the V3-V4 region from the skin of healthy volunteers was consistent with these results, even at the genus level (Staphylococcus, Propionibacterium, Corynebacterium, Paracoccus, Micrococcus, Enhydrobacter and Deinococcus identified at similar abundances on both platforms). The results suggest that the bacterial community diversity captured using the V3-V4 16S rRNA hypervariable region from sequencing using the MiSeq platform is comparable to the Roche454 GS Junior platform. These findings provide evidence that the optimised method can be used in human clinical samples of low bacterial biomass such as the investigation of the skin microbiota.
- 21 January 2017
- Published by Springer Nature in BMC Microbiology
- Vol. 17 (1) , 1-12
Open AccessOptimisation of methods for bacterial skin microbiome investigation: primer selection and comparison of the 454 versus MiSeq platform
The composition of the skin microbiome is predicted to play a role in the development of conditions such as atopic eczema and psoriasis. 16S rRNA gene sequencing allows the investigation of bacterial microbiota. A significant challenge in this field is development of cost effective high throughput methodologies for the robust interrogation of the skin microbiota, where biomass is low. Here we describe validation of methodologies for 16S rRNA (ribosomal ribonucleic acid) gene sequencing from the skin microbiome, using the Illumina MiSeq platform, the selection of primer to amplify regions for sequencing and we compare results with the current standard protocols.. DNA was obtained from two low density mock communities of 11 diverse bacterial strains (with and without human DNA supplementation) and from swabs taken from the skin of healthy volunteers. This was amplified using primer pairs covering hypervariable regions of the 16S rRNA gene: primers 63F and 519R (V1-V3); and 347F and 803R (V3-V4). The resultant libraries were indexed for the MiSeq and Roche454 and sequenced. Both data sets were denoised, cleaned of chimeras and analysed using QIIME. There was no significant difference in the diversity indices at the phylum and the genus level observed between the platforms. The capture of diversity using the low density mock community samples demonstrated that the primer pair spanning the V3-V4 hypervariable region had better capture when compared to the primer pair for the V1-V3 region and was robust to spiking with human DNA. The pilot data generated using the V3-V4 region from the skin of healthy volunteers was consistent with these results, even at the genus level (Staphylococcus, Propionibacterium, Corynebacterium, Paracoccus, Micrococcus, Enhydrobacter and Deinococcus identified at similar abundances on both platforms). The results suggest that the bacterial community diversity captured using the V3-V4 16S rRNA hypervariable region from sequencing using the MiSeq platform is comparable to the Roche454 GS Junior platform. These findings provide evidence that the optimised method can be used in human clinical samples of low bacterial biomass such as the investigation of the skin microbiota.
- 1 June 2016
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 75 (Suppl 2) , 203
THU0068 Absolute Monocyte Counts Are Associated with Adverse EULAR Response after 6 Months of Treatment with A Biologic Agent for Rheumatoid Arthritis
Background Absolute monocyte counts after 3 months of treatment have been found to be predictive of clinical response to adalimumab at 6 months in rheumatoid arthritis (RA) patients1. It has also been shown that resistance to spontaneous apoptosis of monocytes in vitro predicts inadequate response to etanercept2. We hypothesise that absolute monocyte counts obtained from routine pre-treatment blood testing has predictive utility for treatment response to biologic agents. Objectives To assess whether monocytes and other white blood cell subtypes are associated with treatment response at 6 months in RA patients. Methods Full blood count (FBC) data was collected from patients attending 2 centres participating in the Biologics in RA Genetics and Genomics Study Syndicate (BRAGGSS), Manchester Royal Infirmary and Royal Lancaster Infirmary, from 2009–2015. BRAGGSS is a UK-based multi-centre inception cohort of secondary-care RA patients. Spearman correlation was carried out to explore relationships between pre-biologic differential white cell count (WCC) and absolute DAS28 (and its components) at treatment start (baseline) and 6 months. Logistic regression was used to explore associations between differential WCC and EULAR response at 6 months. Stata v13.1 was used for all statistical analyses. Results 130 patients had WCC data available for analysis. They all satisfied American College of Rheumatology 1987 classification criteria for RA. 104 patients (80%) were female, with a mean age of 56.21 (SD 13.07). Mean baseline DAS28 score was 5.96 (SD 0.92) and mean monocyte count at baseline was 0.62*109/L (SD 0.22). Patients were on a variety of biologics: etanercept (n=56), adalimumab (n=24), rituximab (n=13), abatacept (n=10), golimumab (n=5), tocilizumab (n=12) and certolizumab (n=10). Pre-treatment monocyte count was not associated with DAS28 at baseline, but correlated with DAS28 at 6 months (rho=0.19, p=0.028). When a cut-off of 0.62*109/L was used, high monocyte count was associated with DAS28>3.2 at 6 months (OR1.72 [95% CI 1.12–2.64], p=0.013), and with poor EULAR response (OR 2.82 [95% CI 1.12–7.13], p=0.028). Neutrophil count was associated with DAS28 at both baseline (rho=0.22, p=0.013) and 6 months (rho=0.21, p=0.019). Neutrophil count was significantly associated with reduced odds of achieving a good EULAR response at 6 months (OR 0.82 [95% CI 0.69, 0.96], p=0.017). These neutrophil counts likely reflect ongoing inflammation, contributing to poor response to biologic therapy3. Conclusions Monocyte counts were associated with increased DAS28 at 6 months, but not baseline, and with poor EULAR response at 6 months. This could provide a useful and widely available predictive biomarker, as FBC is routinely carried out in all patients commencing disease-modifying therapy in the UK. In future, monocyte count at baseline may be used to predict treatment response to biologics in RA patients at 6 months. Further studies with increased sample size are required to confirm these findings. Chara L et al. Arthritis Res Ther 2012;14:R175. Meusch U et al. Arthritis Res Ther 2013;15:R219. Wright HL et al. Nat Rev Rheumatol 2014;10:593–601. Disclosure of Interest None declared
- 1 June 2016
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 75 (Suppl 2) , 203
THU0068 Absolute Monocyte Counts Are Associated with Adverse EULAR Response after 6 Months of Treatment with A Biologic Agent for Rheumatoid Arthritis
Background Absolute monocyte counts after 3 months of treatment have been found to be predictive of clinical response to adalimumab at 6 months in rheumatoid arthritis (RA) patients1. It has also been shown that resistance to spontaneous apoptosis of monocytes in vitro predicts inadequate response to etanercept2. We hypothesise that absolute monocyte counts obtained from routine pre-treatment blood testing has predictive utility for treatment response to biologic agents. Objectives To assess whether monocytes and other white blood cell subtypes are associated with treatment response at 6 months in RA patients. Methods Full blood count (FBC) data was collected from patients attending 2 centres participating in the Biologics in RA Genetics and Genomics Study Syndicate (BRAGGSS), Manchester Royal Infirmary and Royal Lancaster Infirmary, from 2009–2015. BRAGGSS is a UK-based multi-centre inception cohort of secondary-care RA patients. Spearman correlation was carried out to explore relationships between pre-biologic differential white cell count (WCC) and absolute DAS28 (and its components) at treatment start (baseline) and 6 months. Logistic regression was used to explore associations between differential WCC and EULAR response at 6 months. Stata v13.1 was used for all statistical analyses. Results 130 patients had WCC data available for analysis. They all satisfied American College of Rheumatology 1987 classification criteria for RA. 104 patients (80%) were female, with a mean age of 56.21 (SD 13.07). Mean baseline DAS28 score was 5.96 (SD 0.92) and mean monocyte count at baseline was 0.62*109/L (SD 0.22). Patients were on a variety of biologics: etanercept (n=56), adalimumab (n=24), rituximab (n=13), abatacept (n=10), golimumab (n=5), tocilizumab (n=12) and certolizumab (n=10). Pre-treatment monocyte count was not associated with DAS28 at baseline, but correlated with DAS28 at 6 months (rho=0.19, p=0.028). When a cut-off of 0.62*109/L was used, high monocyte count was associated with DAS28>3.2 at 6 months (OR1.72 [95% CI 1.12–2.64], p=0.013), and with poor EULAR response (OR 2.82 [95% CI 1.12–7.13], p=0.028). Neutrophil count was associated with DAS28 at both baseline (rho=0.22, p=0.013) and 6 months (rho=0.21, p=0.019). Neutrophil count was significantly associated with reduced odds of achieving a good EULAR response at 6 months (OR 0.82 [95% CI 0.69, 0.96], p=0.017). These neutrophil counts likely reflect ongoing inflammation, contributing to poor response to biologic therapy3. Conclusions Monocyte counts were associated with increased DAS28 at 6 months, but not baseline, and with poor EULAR response at 6 months. This could provide a useful and widely available predictive biomarker, as FBC is routinely carried out in all patients commencing disease-modifying therapy in the UK. In future, monocyte count at baseline may be used to predict treatment response to biologics in RA patients at 6 months. Further studies with increased sample size are required to confirm these findings. Chara L et al. Arthritis Res Ther 2012;14:R175. Meusch U et al. Arthritis Res Ther 2013;15:R219. Wright HL et al. Nat Rev Rheumatol 2014;10:593–601. Disclosure of Interest None declared
- Open Access
- 17 May 2015
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 17 (7) , 44-518
Pharmacogenetics of Treatment Response in Psoriatic Arthritis
TNF-blocking agents, non-biological disease-modifying anti-rheumatic drugs (nbDMARDs) and non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed treatments in psoriatic arthritis. A large proportion of patients do not respond to these medications, although unfortunately clinically useful biomarkers that predict future response are currently lacking. Several candidate gene polymorphisms have been associated with responses to biologic therapies and nbDMARDs; however, replication and validation of these variants in large prospective psoriatic arthritis cohorts are required before translating these to clinical practice. In this review, we discuss the advances made in pharmacogenetics of treatment response in psoriatic arthritis to date, with focus on biologic therapies approved for use, nbDMARDs and NSAIDs, as well as outline emerging methodologies to obtain data that will help inform a future precision medicine approach in this condition.
- 17 May 2015
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 17 (7) , 44-518
Open AccessPharmacogenetics of Treatment Response in Psoriatic Arthritis
TNF-blocking agents, non-biological disease-modifying anti-rheumatic drugs (nbDMARDs) and non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed treatments in psoriatic arthritis. A large proportion of patients do not respond to these medications, although unfortunately clinically useful biomarkers that predict future response are currently lacking. Several candidate gene polymorphisms have been associated with responses to biologic therapies and nbDMARDs; however, replication and validation of these variants in large prospective psoriatic arthritis cohorts are required before translating these to clinical practice. In this review, we discuss the advances made in pharmacogenetics of treatment response in psoriatic arthritis to date, with focus on biologic therapies approved for use, nbDMARDs and NSAIDs, as well as outline emerging methodologies to obtain data that will help inform a future precision medicine approach in this condition.